NICE backs NHS use of Takeda’s Adcetris for rare blood cancerTakeda’s antibody-drug conjugate Adcetris should be routinely available on the NHS to patients with a rare form of Share XNICE backs NHS use of Takeda’s Adcetris for rare blood cancerhttps://pharmaphorum.com/news/nice-backs-nhs-use-of-takedas-adcetris-for-rare-blood-cancer/
Sanofi hands back gene therapies to Oxford BiomedicaOxford Biomedica’s long-running alliance with Sanofi over a pair of gene therapies for ophthalmic diseases has come to Share XSanofi hands back gene therapies to Oxford Biomedicahttps://pharmaphorum.com/news/sanofi-hands-back-gene-therapies-to-oxford-biomedica/
CSL, BrightInsight team up on digital health for rare diseasesCSL Behring has signed a deal with US firm BrightInsight to develop digital health products to help patients Share XCSL, BrightInsight team up on digital health for rare diseaseshttps://pharmaphorum.com/news/csl-brightinsight-team-up-on-digital-health-for-rare-diseases/
Menarini bags blood cancer drug with $677M Stemline acquisitionItalian drugmaker Menarini has agreed to buy Stemline Therapeutics, bolting on an already-approved drug for a rare form Share XMenarini bags blood cancer drug with $677M Stemline acquisitionhttps://pharmaphorum.com/news/menarini-bags-blood-cancer-drug-with-677m-stemline-acquisition/
Alnylam files its third RNAi drug lumasiran in rare kidney diseaseGene-silencing specialist Alnylam has completed filings in the US and EU for lumasiran, which aced a phase 3 Share XAlnylam files its third RNAi drug lumasiran in rare kidney diseasehttps://pharmaphorum.com/news/alnylam-files-its-third-rnai-drug-lumasiran-in-rare-kidney-disease/
Delivering change through better rare disease communicationsOPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders Share XDelivering change through better rare disease communicationshttps://deep-dive.pharmaphorum.com/magazine/research-and-development-disruption-2020/delivering-change-through-better-rare-disease-communications/
Takeda signs $882m rare disease alliance with Oxford biotech EvoxEvox Therapeutics is the second UK biotech to sign a big deal with a pharma giant this week, Share XTakeda signs $882m rare disease alliance with Oxford biotech Evoxhttps://pharmaphorum.com/news/takeda-signs-882m-rare-disease-alliance-with-oxford-biotech-evox/
Bringing social media listening into R&DAfter her daughter was diagnosed with Prader-Willi syndrome, Maria Picone used social media listening and AI analytics to Share XBringing social media listening into R&Dhttps://deep-dive.pharmaphorum.com/magazine/research-and-development-disruption-2020/bringing-social-media-listening-rd/
The life-changing burden of my rare diseaseI was first diagnosed with a rare autoimmune disease, Sjogren’s Syndrome, about ten years ago, after several years Share XThe life-changing burden of my rare diseasehttps://pharmaphorum.com/views-analysis-patients/the-life-changing-burden-of-my-rare-disease-sarcoidosis/
